Unisun Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.20 M
- Company Age 21 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.20 M
- Satisfied Charges ₹ 0.50 M
About Unisun Pharma
Unisun Pharma Private Limited (UPPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 June 2003 and has a history of 21 years and eight months. Its registered office is in Bareilly, Uttar Pradesh, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹2.20 M. The company has closed loans amounting to ₹0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Pramod Rana, Anil Sharma, and Umesh Kumar serve as directors at the Company.
Company Details
- Location
Bareilly, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51397UP2003PTC027612
- Company No.
027612
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Jun 2003
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Unisun Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pramod Rana  | Director | 12-Jun-2003 | Current |
| Anil Sharma | Director | 12-Jun-2003 | Current |
| Umesh Kumar | Director | 31-Dec-2014 | Current |
Financial Performance of Unisun Pharma.
Unisun Pharma Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Unisun Pharma?
In 2017, Unisun Pharma had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Prajaswa Infratek Private LimitedPramod Rana is a mutual person
- Dhir Food Company Private Limited
Umesh Kumar is a mutual person
Charges (Loans)
₹2.20 M
₹0.50 M
Charges Breakdown by Lending Institutions
- Others : 0.22 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Mar 2012 | Others | ₹2.20 M | Open |
| 04 Aug 2007 | State Bank Of India | ₹0.50 M | Satisfied |
How Many Employees Work at Unisun Pharma?
Unlock and access historical data on people associated with Unisun Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unisun Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unisun Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
